Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $23.0552W HIGH $56.05
Volume
1.73 M
Value Traded
33.92 M
Short % Float
29.11%
-2.27%Week
-11.99%1 Month
-29.21%3 Month
-33.99%6 Month
+85.1%5 Year
+198.33%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.14 B
EPS (TTM)
-5.58
P/E Ratio
-
Ent. Value
1.72 B
Total Shares
72.08 M
Float Shares
58.51 M
Insiders
18.81%
Institutions
98.38%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
VERA Catalyst Timeline
Dated clinical, regulatory and corporate events for Vera Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vera Therapeutics, Inc.
295Total events
18Upcoming
82Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutTRUTAKNAApprovedClinical Data
TRUTAKNA ORIGIN 3 final efficacy analysis topline results announced
IgA nephropathysource ↗
▲Primary Endpoint MetTRUTAKNAApprovedClinical Data
ORIGIN 3 met all prespecified endpoints including eGFR stabilization and 76% risk reduction in composite kidney disease progression
IgA nephropathysource ↗
▲Secondary Endpoint DataTRUTAKNAApprovedClinical Data
Statistically significant reductions in proteinuria, Gd-IgA1 and hematuria
primary IgA nephropathy (IgAN)source ↗
▲Safety Data UpdateTRUTAKNAApprovedClinical Data
ORIGIN 3 final analysis safety profile favorable and comparable to placebo
primary IgA nephropathy (IgAN)source ↗
▲Product LaunchTRUTAKNAApprovedPost-Market
Over 350 patient start forms generated in first ten weeks of launch
primary IgA nephropathy (IgAN)source ↗
▲Product LaunchTRUTAKNAApprovedPost-Market
Over 350 patient start forms generated in first ten weeks of TRUTAKNA launch
IgA nephropathysource ↗
▲Accelerated ApprovalTRUTAKNAApprovedFDA Decision
TRUTAKNA granted accelerated approval by FDA
primary IgA nephropathy (IgAN)source ↗
▲FDA Feedback ReceivedTRUTAKNAApprovedFDA Meeting
Alignment with FDA on earlier ORIGIN 3 final efficacy analysis
primary IgA nephropathy (IgAN)source ↗
▲FDA ApprovalTRUTAKNAApprovedFDA Decision
FDA accelerated approval for TRUTAKNA to reduce proteinuria in adults with primary IgAN
primary IgA nephropathysource ↗
▲Topline ReadoutTRUTAKNAApprovedClinical Data
Topline results from prespecified 36-week interim analysis of ORIGIN 3
primary IgA nephropathysource ↗
▲Primary Endpoint MetTRUTAKNAApprovedClinical Data
Primary endpoint met in ORIGIN 3 interim analysis
primary IgA nephropathysource ↗
▲Secondary Endpoint DataTRUTAKNAApprovedClinical Data
Secondary endpoint of Gd-IgA1 reduction reported
primary IgA nephropathysource ↗
●Oral PresentationTRUTAKNAApprovedPresentation
Investor webcast discussing accelerated approval of TRUTAKNA
primary IgA nephropathysource ↗
◆Topline ReadoutAtaciceptApprovedClinical Data
Revised ORIGIN 3 eGFR analysis results expected Q3 2026
IgA Nephropathysource ↗
◆Topline ReadoutTRUTAKNAApprovedClinical Data
Topline eGFR results from ORIGIN 3 confirmatory trial
primary IgA nephropathysource ↗
◆Timing GuidanceTRUTAKNAApprovedPresentation
Confirmatory eGFR results anticipated in Q3 2026
primary IgA nephropathysource ↗
▲Accelerated ApprovalTRUTAKNAApprovedFDA Decision
TRUTAKNA (atacicept-vymj) approved under accelerated approval to reduce proteinuria in adults with primary IgAN
primary immunoglobulin A nephropathy (IgAN)source ↗
◆Product LaunchAtaciceptApprovedPost-Market
Planned U.S. commercial launch of atacicept
IgA Nephropathy (IgAN)source ↗
◆Oral PresentationPresentation
Vera Therapeutics management presents at Bank of America Securities 2026 Health Care Conference
▲Priority ReviewAtaciceptApprovedRegulatory Filing
FDA granted priority review to atacicept BLA for IgAN
IgA Nephropathy (IgAN)source ↗
◆Topline ReadoutAtaciceptApprovedClinical Data
Initial results from PIONEER Phase 2 basket trial
IgAN and other autoimmune kidney diseasessource ↗
◆FDA ApprovalAtaciceptApprovedFDA Decision
Potential FDA approval and U.S. commercial launch of atacicept in IgAN expected mid-2026
IgANsource ↗
▲Priority ReviewAtaciceptApprovedRegulatory Filing
BLA for atacicept granted priority review by FDA
IgANsource ↗
◆Oral PresentationPresentation
Vera Therapeutics management to present at 44th Annual J.P. Morgan Healthcare Conference
▲FDA Filing AcceptedAtaciceptApprovedRegulatory Filing
FDA accepted BLA for atacicept for IgAN
IgA nephropathysource ↗
▲Priority ReviewAtaciceptApprovedRegulatory Filing
FDA granted Priority Review for atacicept BLA
IgA nephropathysource ↗
▲FDA ApprovalTRUTAKNAApprovedFDA Decision
Accelerated approval of TRUTAKNA (atacicept-vymj) for IgAN
IgA nephropathy (IgAN)source ↗
▼Equity OfferingCorporate
Pricing of underwritten public offering of 6,138,108 shares at $42.50 per share
◆Oral PresentationPresentation
Vera Therapeutics management team presents at TD Cowen Immunology & Inflammation Summit
●BLA SubmissionAtaciceptApprovedRegulatory Filing
BLA submitted to FDA through Accelerated Approval Program for atacicept in IgAN
IgA nephropathysource ↗
▲Primary Endpoint MetAtaciceptApprovedClinical Data
ORIGIN 3 interim analysis met primary endpoint of proteinuria reduction at week 36
IgA nephropathysource ↗
◆Oral PresentationAtaciceptApprovedPresentation
ORIGIN Phase 3 data presented at ASN Kidney Week 2025 morning plenary session
IgA nephropathysource ↗
▲PublicationAtaciceptApprovedPresentation
ORIGIN Phase 3 data published in New England Journal of Medicine
IgA nephropathysource ↗
▲Late-BreakerAtaciceptApprovedPresentation
ORIGIN Phase 3 data presented as late-breaking oral at ASN Kidney Week 2025
IgA nephropathysource ↗
◆Poster PresentationAtaciceptApprovedPresentation
PIONEER basket trial poster presentation at ASN Kidney Week 2025
Autoimmune mediated glomerular diseasesource ↗
◆Oral PresentationAtaciceptApprovedPresentation
Late-breaking presentation of ORIGIN 3 data at ASN Kidney Week
IgANsource ↗
Past FDA Catalysts and PDUFA Decisions
How VERA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | atacicept | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D36 / 100
Pipeline Score
$268M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 52%
Small Cap(rank 343 of 658)
Percentile Rank
Vera Therapeutics, Inc. faces pipeline headwinds (36/100), with $459M risk-adjusted pipeline value, led by Atacicept in pMN (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Atacicept Small moleculeMarketedNCT07020923 | IgA Nephropathy | Phase 3 | ACTIVE NOT_RECRUITING | 1,268 | Sep 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every VERA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Atacicept BreakthroughPriorityAccelerated | 2025-11-06 | UPCR reduction: 42%; Gd Ig A1 reduction: -68%; hematuria resolution odds ratio: 19.1Read More | Primary Endpoint: UPCR Reduction Interim Analysis Set (IAS) included the first 203 randomized participants who received 1 dose of trial drug. Change from baseline in natural-log transformed UPCR at Week 36 was analyzed uRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Fordyce MarshallDirector, Officer (PRESIDENT AND CEO) | Option | 18,500 253,744 held | $2.90 | 09/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VERA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 2.2 % (-4.3 %) | 245.61 M | 5.72 M | -2.8% ( -165.00 K) |
VERA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VERA ranks across every disease it competes in
Competitive Position is a premium feature
See how VERA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVERA News
VERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced the granting of inducement awards to five new employees, which include stock options and restricted stock units. The awards were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $32.38 and will vest over four years. This move reflects the company's commitment to attract talent as it continues to grow.
Read more →VERAVera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
Vera Therapeutics announced that the final efficacy analysis of TRUTAKNA will be presented at ASN Kidney Week 2026. This includes a late-breaking oral presentation and a poster session. Additionally, interim results from a Phase 2 trial will also be shared. The company aims to advance treatment options for IgA nephropathy.
Read more →VERAVera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
Vera Therapeutics announced that TRUTAKNA achieved all prespecified endpoints in the ORIGIN 3 trial for IgA nephropathy, showing significant stabilization of eGFR and reduced kidney disease progression over two years. The product is set for a supplemental BLA submission to the FDA in Q4 2026 for full approval. The initial commercial launch has generated strong interest, with over 350 patient start forms in the first ten weeks.
Read more →VERAVera Therapeutics to Participate at Upcoming Investor Conferences
Vera Therapeutics, a biotechnology company, announced its participation in upcoming investor conferences, including the Cantor Global Healthcare Conference and the Morgan Stanley Global Healthcare Conference. The management team will present and hold one-on-one meetings with investors. The company is focused on developing treatments for autoimmune diseases, particularly through its product TRUTAKNA.
Read more →VERAVera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
Vera Therapeutics announced that its drug TRUTAKNA™ has received accelerated approval from the FDA for treating adult patients with primary IgA nephropathy who are at risk for disease progression. The company has also aligned with the FDA on the final efficacy analysis for a potential full approval. This marks a significant milestone for the company.
Read more →VERAVera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
Vera Therapeutics announced the retirement of William Turner as Chief Regulatory Officer, transitioning him to a Strategic Advisor role. Nancy Boman, with over 25 years of regulatory experience, will succeed him. This leadership change follows the recent accelerated approval of TRUTAKNA for IgA nephropathy, marking a significant milestone for the company.
Read more →VERAVera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
Vera Therapeutics has received FDA accelerated approval for TRUTAKNA, the first therapy targeting both BAFF and APRIL for adults with primary IgA nephropathy (IgAN). In the ORIGIN 3 trial, TRUTAKNA demonstrated a 46% reduction in proteinuria compared to baseline and a 42% reduction compared to placebo. While generally well tolerated, the long-term impact on kidney function is yet to be established, and ongoing trials will determine continued approval.
Read more →VERA▼ -7.9%on this newsshared move
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
Vera Therapeutics has aligned with the FDA to conduct an earlier analysis of eGFR for atacicept, aimed at supporting its full approval for treating IgA Nephropathy. The revised analysis is now scheduled for Q3 2026, with a supplemental Biologics License Application planned for Q4 2026. The ORIGIN Phase 2b trial showed significant results, indicating the potential of atacicept as a leading therapy in this area.
Read more →VERAVera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
Vera Therapeutics reported a business update and financial results for Q1 2026, highlighting FDA's priority review of atacicept for IgA Nephropathy with a PDUFA date set for July 7, 2026. The company is preparing for a U.S. commercial launch of atacicept in mid-2026, supported by a strong balance sheet. However, the company reported a significant increase in net loss compared to the previous year.
Read more →VERAVera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference
Vera Therapeutics will present at the Bank of America Securities 2026 Health Care Conference in Las Vegas from May 12-14, 2026. The management team is scheduled to speak on May 13 at 4:20 PM PDT and will also hold one-on-one investor meetings. The company focuses on innovative treatments for serious immunological diseases.
Read more →VERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 27, 2026
Vera Therapeutics announced inducement grants for its new Chief Legal Officer, Jane Wright-Mitchell, consisting of stock options and restricted stock units. The awards, totaling 56,850 stock options and 42,403 RSUs, are part of the company's 2024 Inducement Plan and aim to incentivize the new hire. The stock options will vest over four years, aligning with the company's strategy to attract top talent.
Read more →VERAVera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
Vera Therapeutics has appointed Jane Wright-Mitchell as Chief Legal Officer, effective immediately. With over 25 years of experience in the life sciences sector, she will lead legal efforts as the company approaches the launch of its dual BAFF/APRIL inhibitor for IgA nephropathy. Her previous roles include General Counsel at Vaxcyte, Inc., and she aims to strengthen Vera's foundation for sustainable success.
Read more →VERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 6, 2026
Vera Therapeutics announced inducement grants for six new employees, consisting of stock options and restricted stock units. The awards are part of the company's 2024 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $39.30 and will vest over four years. Vera Therapeutics focuses on developing treatments for serious immunological diseases.
Read more →About Vera Therapeutics, Inc.
Headquarters2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE, CA, 94005
BIOPHARMAWATCH ELITE PLUS
Trade the next VERA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime